Orexo AB Presents an Update on the U.S. Opioid Dependence Market, and the Commercial Opportunities for Zubsolv™ (OX219)
9/21/2012 10:13:30 AM
UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo (STO:ORX): The Swedish specialty pharmaceutical company Orexo presents today its view on the future market for treatment of opioid dependence in the US. Opioid dependence is a clinical condition, which increasingly is being recognized as having a major societal impact and financial cost. Recent estimates indicate that in the US the cost to society of opioid dependence reached USD 55.7 Bn. Based on the continued growth in utilization of prescription based opioid products in US, and the associated growth in non-medical use of Rx-opioids, Orexo projects the US market for treatment of opioid dependence to continue growing and to reach USD 2 Bn in value by 2014. In addition to these main drivers, the recent years have yielded an increasing number of patients seeking treatment for their opioid dependence, and data suggest that patients also are likely to be treated over longer periods. Orexo will at the meeting also present the basis for the projected peak sales potential for Zubsolv previously stated to USD 500 mio.